|
|
||||||||
Ann Thorac Surg 2003;75:S649-S655
© 2003 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, The University of Washington, Seattle, Washington, USA
b Departments of Immunology and Vascular Biology, The Scripps Research Institute, La Jolla, California, La Jolla, California, USA
* Address reprint requests to Dr Pohlman, Division of Trauma and Critical Care, Department of Surgery, The University of Washington, Box 359796, 325 9th Avenue, Seattle, WA 98104, USA
e-mail: tpohlman{at}u.washington.edu
Presented at the 3rd International Symposium on Myocardial Protection From Surgical Ischemic-Reperfusion Injury, Asheville, NC, June 26, 2002.
Abstract
Reperfusion of the ischemic heart is necessary to prevent irreversible injury of the myocardium, which leads to permanent organ dysfunction. However, reperfusion in itself leads to myocardial ischemia/reperfusion (I/R) injury, which is characterized by an acute inflammatory response mediated by activated inflammatory cells, chemokines, cytokines, and adhesion molecules. The molecular mechanisms of myocardial I/R injury are not completely known. Tissue factor (TF) and thrombin, two potent procoagulant and proinflammatory mediators, are recognized to play significant roles in myocardial I/R injury. To investigate the role of TF and thrombin in myocardial I/R injury, we used rabbit and murine in situ coronary artery ligation models. Increased TF mRNA, antigen, and activity were found in ischemic cardiomyocytes. Administration of an inhibitory antirabbit TF monoclonal antibody before or during the onset of ischemia resulted in a significant reduction in infarct size. Functional inhibition of thrombin with hirudin also reduced the infarct size. However, defibrinogenating rabbits with ancrod had no effect on infarct size, suggesting a requirement of thrombin generation but not fibrin deposition in myocardial I/R injury.
This article has been cited by other articles:
![]() |
J. L. Strande, A. Hsu, J. Su, X. Fu, G. J. Gross, and J. E. Baker Inhibiting Protease-Activated Receptor 4 Limits Myocardial Ischemia/Reperfusion Injury in Rat Hearts by Unmasking Adenosine Signaling J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1045 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Farivar, M. F. Delgado, A. S. McCourtie, A. D. Barnes, E. D. Verrier, and M. S. Mulligan Crosstalk Between Thrombosis and Inflammation in Lung Reperfusion Injury. Ann. Thorac. Surg., March 1, 2006; 81(3): 1061 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ikonomidis, G. Athanassopoulos, J. Lekakis, K. Venetsanou, M. Marinou, K. Stamatelopoulos, D. V. Cokkinos, and P. Nihoyannopoulos Myocardial Ischemia Induces Interleukin-6 and Tissue Factor Production in Patients With Coronary Artery Disease: A Dobutamine Stress Echocardiography Study Circulation, November 22, 2005; 112(21): 3272 - 3279. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jormalainen, A. E. Vento, U. Wartiovaara-Kautto, R. Suojaranta-Ylinen, O. J. Ramo, and J. Petaja Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 189 - 196. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |